tiprankstipranks
Trending News
More News >
Palisade Bio (PALI)
NASDAQ:PALI

Palisade Bio (PALI) AI Stock Analysis

Compare
529 Followers

Top Page

PA

Palisade Bio

(NASDAQ:PALI)

Rating:45Neutral
Price Target:
Palisade Bio's financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
Positive Factors
Drug Development
The management's focus on developing PALI-2108 for fibrostenotic Crohn’s disease represents a strategic decision as there are currently no FDA approved therapies for this condition.
Drug Potency
PALI-2108 has been found to be 20 times more potent than apremilast, thanks to its localized delivery to targeted tissue.
Safety Profile
PALI-2108 was found to be safe and well-tolerated in the Phase 1a trial, with no serious adverse events reported.
Negative Factors
Financing Needs
Palisade Bio will require another financing following the data, which may be more dilutive given the current market dynamics.
Price Target
The analyst's recommendation includes a lower 12-month price target due to expected dilution from future financing needs.

Palisade Bio (PALI) vs. SPDR S&P 500 ETF (SPY)

Palisade Bio Business Overview & Revenue Model

Company DescriptionPalisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's core product candidates are designed to address unmet medical needs in the fields of gastrointestinal health, specifically targeting conditions such as inflammatory bowel disease (IBD) and postoperative digestive complications. Utilizing its proprietary technology, Palisade Bio aims to create innovative treatments that improve patient outcomes and quality of life.
How the Company Makes MoneyPalisade Bio makes money primarily through the development and commercialization of its drug candidates. The company seeks to generate revenue by bringing its therapeutics to market, either independently or through strategic partnerships with larger pharmaceutical companies. These partnerships may involve licensing agreements, co-development deals, or milestone payments, which provide Palisade Bio with funding and shared resources. The company's revenue streams are heavily reliant on successful clinical trials, regulatory approvals, and the ability to effectively market its products to healthcare providers and patients. Additionally, Palisade Bio may secure funding through grants or investments to support its research and development efforts.

Palisade Bio Financial Statement Overview

Summary
Overall, Palisade Bio is struggling financially with consistent losses and negative cash flow. The balance sheet shows some stability due to low leverage, but the lack of revenue growth and profitability are significant concerns. The company heavily relies on external financing, which may not be sustainable long-term.
Income Statement
20
Very Negative
Palisade Bio shows no revenue growth and has been operating at a loss consistently. The gross profit margin is null due to no revenues, and the company faces a significant negative net profit margin, indicating poor profitability. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.
Balance Sheet
60
Neutral
The company has maintained a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the equity ratio has been fluctuating, with a recent decline in stockholders' equity. Despite this, Palisade Bio maintains more equity than debt, providing some stability.
Cash Flow
30
Negative
Palisade Bio's cash flow situation is concerning with negative free cash flow and operating cash flow. The company has been relying on financing activities to cover its negative cash flows, which poses sustainability risks. The free cash flow to net income ratio is negative, indicating cash flow issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.00250.00K0.000.0013.52K
Gross Profit-1.00K0.00250.00K-167.00K-168.00K-132.00K
EBITDA-13.13M-14.86M-12.28M-15.15M-24.05M-9.94M
Net Income-13.14M-14.44M-12.30M-14.26M-26.62M-10.32M
Balance Sheet
Total Assets8.19M10.88M14.05M15.76M12.51M3.02M
Cash, Cash Equivalents and Short-Term Investments7.23M9.82M12.43M12.38M10.49M713.00K
Total Debt58.00K169.00K369.00K404.00K199.00K1.42M
Total Liabilities2.86M3.39M2.74M3.28M5.15M19.62M
Stockholders Equity5.33M7.49M11.31M12.48M7.37M-16.60M
Cash Flow
Free Cash Flow-11.35M-12.19M-11.14M-13.37M-14.77M-4.77M
Operating Cash Flow-11.35M-12.19M-11.13M-13.36M-14.77M-4.77M
Investing Cash Flow0.000.00-4.00K-10.00K-54.00K-6.00K
Financing Cash Flow7.30M9.58M11.19M15.26M24.61M1.89M

Palisade Bio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.73
Price Trends
50DMA
0.72
Positive
100DMA
0.77
Negative
200DMA
1.61
Negative
Market Momentum
MACD
<0.01
Negative
RSI
53.86
Neutral
STOCH
70.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Positive. The current price of 0.73 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.72, and below the 200-day MA of 1.61, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.86 is Neutral, neither overbought nor oversold. The STOCH value of 70.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PALI.

Palisade Bio Risk Analysis

Palisade Bio disclosed 48 risk factors in its most recent earnings report. Palisade Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Palisade Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
HK$15.37B5.69-7.44%4.08%11.55%-28.15%
45
Neutral
$3.48M-170.72%-100.00%53.88%
34
Underperform
$6.87M-190.70%14.28%
29
Underperform
$4.30M-91.32%48.81%
28
Underperform
$4.13M-49.58%71.41%
25
Underperform
$5.22M-138.80%42.26%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PALI
Palisade Bio
0.73
-3.69
-83.48%
GLMD
Galmed Pharmaceuticals
1.83
-1.73
-48.60%
QNRX
Quoin Pharmaceuticals
8.88
-12.05
-57.57%
ARTL
Artelo Biosciences
15.90
7.95
100.00%
GLTO
Galecto
3.25
-9.39
-74.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025